Wegovy 7.5 mg: What the Dose Schedule Actually Looks Like

You searched for 7.5 mg, but here's what the packaging actually says

Imagine you've been on Wegovy for several months and someone in your slimming group mentions a higher dose, "7.5 mg". You google it, find a handful of forum threads, maybe a grey-market listing, and wonder whether your prescriber has kept you in the dark. They haven't. The dose simply isn't real.

The confusion almost certainly traces back to the new 7.2 mg pen. When the MHRA approved the 7.2 mg single-dose Wegovy pen on 14 April 2026, it generated a wave of coverage, and "7.2" and "7.5" are close enough that the figure gets garbled in transcription, social media posts and unofficial sites. A grey-market seller listing "Wegovy 7.5 mg" is not offering a higher dose; they're offering either a mislabelled product or something that isn't Wegovy at all.

The six licensed UK strengths are 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg. Each pen contains four weekly doses except the 7.2 mg pen, which is a single pre-set weekly injection with a built-in covered needle that locks after use. The full Wegovy dose schedule explains what each rung is for and roughly when you'd expect to move between them. You can also read the NHS semaglutide medicines page for a patient-level overview of the schedule and common side effects.

Worth checking any site that lists a strength you don't recognise against the GPhC register before you spend a penny.

What the 7.2 mg dose actually does, and who it's for

The 7.2 mg pen is the ceiling of the Wegovy schedule. It was first approved by the MHRA at a dosing level of three 2.4 mg pens administered weekly (a cumbersome interim step) before the dedicated single-dose pen arrived in April 2026. That pen is licensed for adults with a BMI of 30 or above; it is not available for the cardiovascular indication or for BMI below that threshold.

In trials, participants on 7.2 mg semaglutide lost around 20.7% of body weight on average over 72 weeks. That narrows the distance from tirzepatide's headline figures considerably. If you've been reading about how Wegovy works and wondering whether the highest dose is meaningfully different from 2.4 mg, the honest answer is yes, but "meaningfully higher dose" also means a higher side-effect burden for some people, which is precisely why the step-up happens gradually over many months and why the prescriber's eye on your progress matters.

The starting point is always 0.25 mg, a low introductory strength chosen to let your system adjust before any therapeutic effect kicks in. Skipping steps isn't an option under the licensed schedule. If you're curious about what the typical maintenance dose looks like for most patients, 2.4 mg remains the most common endpoint.

Storage note: whatever dose you're on, Wegovy needs to live in the fridge, 2 to 8°C. Most people keep it in the fridge door, which works fine as long as it doesn't freeze. For the exact room-temperature window if you're travelling, the Patient Information Leaflet has the definitive figures rather than anything you'll read on a website.

Side effects at higher doses (what to expect as you step up

Gastrointestinal effects) nausea, looser stools, reflux, reduced appetite, are Wegovy's most reported side effects at every dose. They tend to peak after a step-up and ease within a week or two for most people, though not everyone. Moving to a higher dose doesn't reset that pattern to zero; if 1.7 mg gave you two uncomfortable weeks, reaching 2.4 mg or eventually 7.2 mg may do the same, though many people find later steps easier because their system has already adapted.

The MHRA has also highlighted acute pancreatitis as a known but infrequent risk with GLP-1 medicines. Severe, persistent stomach pain that radiates toward the back (especially with or without vomiting) is the sign to stop the injection and get medical help the same day, not to wait for your next review. Report any side effect you're uncertain about through the Yellow Card scheme; that's how the regulator tracks signals across the whole population using these medicines.

If your dose has recently changed and you're unsure what's normal adjustment versus something that needs attention, our aftercare team is available seven days a week, you don't need to wait until your next scheduled review. A question our prescribers hear most weeks is whether a particular symptom is dose-related or something else: the answer almost always requires knowing your full picture, not a forum's best guess.

How dose decisions are made in practice

Dose titration isn't a calendar you follow mechanically. The prescriber looks at how much weight you've lost, what side effects you've experienced, and whether there's a clinical reason to stay longer at the current strength before moving up. Staying at 1.7 mg for longer than four weeks isn't a failure, it can be the right call. Moving straight to the maximum isn't always the target either; some people do well at 2.4 mg and have no reason to step further.

For context on what drives those decisions, an overview of the Wegovy strengths covers each dose's place in the schedule. If you're weighing up Wegovy against other licensed options, you can read more on the weight-loss treatments overview or look at what private Wegovy treatment costs in the UK, a transparent picture of what an all-inclusive private prescription involves. When you're ready to talk through whether Wegovy is the right fit for you, speak to our prescribers through a free consultation, reviewed by a real clinician the same day.